Evidence map›Paper›PMID 31887283›Full record

ReviewChest2020

Machine Learning Characterization of COPD Subtypes: Insights From the COPDGene Study.

Peter J Castaldi, Adel Boueiz, Jeong Yun, Raul San Jose Estepar, James C Ross, George Washko, Michael H Cho, Craig P Hersh, Gregory L Kinney, Kendra A Young and 11 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 75 citations in OpenAlex.

  1. Trial
  2. Preclinical models of COPD: a state of the art review.The European respiratory journal · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Peter J CastaldiChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; General Medicine and Primary Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: repjc@channing.harvard.edu.
Adel BoueizChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jeong YunChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Raul San Jose EsteparApplied Chest Imaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
James C RossApplied Chest Imaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
George WashkoPulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Applied Chest Imaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Michael H ChoChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Craig P HershChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Gregory L KinneyDepartment of Epidemiology, University of Colorado, Denver, Aurora, CO.
Kendra A YoungDepartment of Epidemiology, University of Colorado, Denver, Aurora, CO.
Elizabeth A ReganNational Jewish Health, Denver, CO.
David A LynchDepartment of Radiology, National Jewish Health, Denver, CO.
Gerald J CrinerDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Jennifer G DyDepartment of Electrical and Computer Engineering, Northeastern University, Boston, MA.
Stephen I RennardPulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE.
Richard CasaburiRehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
Barry J MakeNational Jewish Health, Denver, CO.
James CrapoNational Jewish Health, Denver, CO.
Edwin K SilvermanChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
John E HokansonDepartment of Epidemiology, University of Colorado, Denver, Aurora, CO.
COPDGene Investigators
University of Colorado Denver · USBrigham and Women's Hospital · USHarvard University · USNational Jewish Health · USUniversity of Nebraska Medical Center · USNortheastern University · USTemple University · USThe Lundquist Institute · US

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
Using Integrative Genomics To Identify and Characterize Emphysema-Associated eQTLR01HL124233 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CASTALDI, PETER · 2014 to 2024
$7.1M
Ultra-low Dose, High Speed, High Resolution, Multispectral, Multi-Source MDCT ScaS10OD018526 · OD · UNIVERSITY OF IOWA · PI HOFFMAN, ERIC ALFRED · 2015 to 2015
$2.0M
Prospective Health Outcomes and Inflammatory Biomarkers Associated with e-Cigarette UseR01HL147326 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CASTALDI, PETER · 2019 to 2021
$1.5M
Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokersK08HL141601 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI EL BOUEIZ, ADEL · 2018 to 2022
$853k
The role of COPD genetic risk factor HHIP on lymphocytic inflammationK08HL146972 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI YUN, JEONG H · 2020 to 2024
$848k
NHLBI NIH HHS K08 HL141601NHLBI NIH HHS K08 HL146972NHLBI NIH HHS R01 HL124233NHLBI NIH HHS R01 HL147326NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NIH HHS S10 OD018526
6 · The paper itself

Abstract

COPD is a heterogeneous syndrome. Many COPD subtypes have been proposed, but there is not yet consensus on how many COPD subtypes there are and how they should be defined. The COPD Genetic Epidemiology Study (COPDGene), which has generated 10-year longitudinal chest imaging, spirometry, and molecular data, is a rich resource for relating COPD phenotypes to underlying genetic and molecular mechanisms. In this article, we place COPDGene clustering studies in context with other highly cited COPD clustering studies, and summarize the main COPD subtype findings from COPDGene. First, most manifestations of COPD occur along a continuum, which explains why continuous aspects of COPD or disease axes may be more accurate and reproducible than subtypes identified through clustering methods. Second, continuous COPD-related measures can be used to create subgroups through the use of predictive models to define cut-points, and we review COPDGene research on blood eosinophil count thresholds as a specific example. Third, COPD phenotypes identified or prioritized through machine learning methods have led to novel biological discoveries, including novel emphysema genetic risk variants and systemic inflammatory subtypes of COPD. Fourth, trajectory-based COPD subtyping captures differences in the longitudinal evolution of COPD, addressing a major limitation of clustering analyses that are confounded by disease severity. Ongoing longitudinal characterization of subjects in COPDGene will provide useful insights about the relationship between lung imaging parameters, molecular markers, and COPD progression that will enable the identification of subtypes based on underlying disease processes and distinct patterns of disease progression, with the potential to improve the clinical relevance and reproducibility of COPD subtypes.

Indexed as

Machine LearningMolecular EpidemiologyCluster AnalysisDiagnostic ImagingDisease ProgressionGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansPhenotypePulmonary Disease, Chronic ObstructiveRespiratory Function TestsCOPDemphysemamachine learning

Identifiers

PMID31887283
PMCPMC7242638
OpenAlexW2998687433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.